<p>上涨的东西也会下跌。大多数投资者都亲身经历过他们投资组合中的股票的这种情况。但是，下跌的东西能否再次上涨？在许多情况下，答案是肯定的。</p>
<p>股票价格的急剧下跌往往为长期投资者提供了绝佳的买入机会。我认为现在就存在这样的机会。以下是两只被严重低估的股票，具有令人难以置信的上涨潜力。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjkwOTYvc3RvY2stY2hhcnQtdHJlbmRpbmctZG93bi13aXRoLW1hbi5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjkwOTYvc3RvY2stY2hhcnQtdHJlbmRpbmctZG93bi13aXRoLW1hbi5qcGcmdz03MDA"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. 联合健康集团</h2>
<p><strong>联合健康集团</strong>（UNH 1.21%）的股价已大约下跌了 50%，低于今年早些时候的高点。几乎所有可能出错的事情都在这家健康保险公司的股票上发生了。</p>
<p>在四月份，联合健康集团公布了令人失望的第一季度业绩，并下调了全年的指引。不到一个月后，该公司完全暂停了全年的展望，并在前首席执行官安德鲁·维蒂意外离职后任命了一位新首席执行官。</p>
<p>这并不是唯一的坏消息。《华尔街日报》在五月份报道，美国司法部正在对联合健康集团的医疗保险账单做法进行民事和刑事调查。该公司在七月份确认这些调查确实正在进行中。</p>
<p>但联合健康集团在前首席执行官斯蒂芬·赫姆斯利的掌舵下，依然处于良好的管理之中。该公司当前的财务困境源于高于预期的医疗成本，特别是在其医疗保险优势计划中。这些问题可以通过提高保费来解决，而这正是联合健康计划在 2026 年要做的。</p>
<p>当然，与司法部调查相关的阴云将在一段时间内继续笼罩在公司头上。之前的一次联邦调查持续了十年。然而，在那次调查中没有发现任何不当行为的证据。联合健康集团似乎相信这次也会有类似的结果，公司表示 “对其做法充满信心”。</p>
<p>亿万富翁投资者沃伦·巴菲特和大卫·泰珀，以及因《大空头》而闻名的迈克尔·伯里，在 2025 年第二季度购买了这家医疗巨头的股票。他们无疑认为联合健康集团的估值具有吸引力，其市盈率处于多年来的最低水平。</p>
<p>我怀疑巴菲特、泰珀和伯里对联合健康集团的前景是正确的。一旦公司的收益在明年开始再次增长，这只被严重低估的股票可能会强劲反弹。</p>
<h2>2. Vertex 制药</h2>
<p><strong>Vertex 制药</strong>（VRTX 0.69%）在今年早些时候表现出色。然而，这种势头现在已经消失。该生物技术股票的股价已下跌超过 20%，低于 2025 年 3 月的峰值。</p>
<p>Vertex 的第一个警告信号出现在五月，该公司公布的第一季度业绩低于预期。收入低于分析师的预测，主要是由于公司在俄罗斯销售的仿制版囊性纤维化（CF）药物影响了销售。</p>
<p>Vertex 本月早些时候宣布了两个管道挫折。实验性止痛药 VX-993 未能达到二期临床试验的主要终点。该公司还透露，美国食品和药物管理局（FDA）未看到为 Journavx 在治疗外周神经病理性疼痛（PNP）提供广泛标签的前景。</p>
<p>尽管这一消息令人失望，但 Vertex 的积极因素仍然多于消极因素。Journavx 在美国的推出进展顺利，公司正在加强其商业化努力。其最新的 CF 疗法 Alyftrek 在市场上持续获得动力。Journavx 和 Alyftrek 都应该在不久的将来成为 Vertex 的巨大畅销药。</p>
<p>Vertex 的管道前景仍然看好。该生物技术公司预计将在明年申请 1 型糖尿病疗法 zimislecel 的全球监管批准，并申请 FDA 加速批准 povetacicept 用于治疗 IgA 肾病。针对 APOL1 介导的肾病的晚期临床研究也在进行中。尽管 FDA 目前对 Journavx 的广泛 PNP 标签泼了冷水，但 Vertex 仍在推进三期研究，以争取在糖尿病外周神经病变中获得批准。</p>
<p>华尔街对这只生物技术股票的 12 个月共识目标价反映出超过 21% 的上涨潜力。如果 Vertex 的已批准产品和管道候选药物兑现其承诺，其股票在未来几年内应该能够大幅飙升。</p>

福泰制药

联合健康

<p>这篇文章讨论了两只表现不佳但具有显著上涨潜力的股票：联合健康和福泰制药。联合健康由于令人失望的业绩和持续的调查，股价下跌了 50%，但随着新领导层的上任和提高保费的计划，它可能会反弹。福泰制药由于销售疲软和管道问题下跌超过 20%，然而它有前景良好的产品和即将获得的监管批准，这表明在未来几年内有恢复和增长的潜力</p>

<p>What goes up can come down. Most investors have experienced this first-hand with stocks in their portfolio. But can what comes down go back up? In many cases, the answer is a resounding yes.</p>
<div class="lb-trans"><p>上涨的东西也会下跌。大多数投资者都亲身经历过他们投资组合中的股票的这种情况。但是，下跌的东西能否再次上涨？在许多情况下，答案是肯定的。</p>
</div><p>Steep declines in share prices can often present great buying opportunities for long-term investors. I think such opportunities exist right now. Here are two beaten-down stocks with incredible upside potential.</p>
<div class="lb-trans"><p>股票价格的急剧下跌往往为长期投资者提供了绝佳的买入机会。我认为现在就存在这样的机会。以下是两只被严重低估的股票，具有令人难以置信的上涨潜力。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjkwOTYvc3RvY2stY2hhcnQtdHJlbmRpbmctZG93bi13aXRoLW1hbi5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F829096%2Fstock-chart-trending-down-with-man.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. UnitedHealth Group</h2>
<div class="lb-trans"><h2>1. 联合健康集团</h2>
</div><p>Shares of <strong>UnitedHealth Group</strong>(UNH 1.21%) have plunged roughly 50% below the high from earlier this year. Pretty much everything that could go wrong for the health insurance stock has gone wrong.</p>
<div class="lb-trans"><p><strong>联合健康集团</strong>（UNH 1.21%）的股价已大约下跌了 50%，低于今年早些时候的高点。几乎所有可能出错的事情都在这家健康保险公司的股票上发生了。</p>
</div><p>In April, UnitedHealth Group announced disappointing first-quarter results and lowered its guidance for the full year. Less than one month later, the company suspended its full-year outlook altogether and named a new CEO after the unexpected departure of former CEO Andrew Witty.</p>
<div class="lb-trans"><p>在四月份，联合健康集团公布了令人失望的第一季度业绩，并下调了全年的指引。不到一个月后，该公司完全暂停了全年的展望，并在前首席执行官安德鲁·维蒂意外离职后任命了一位新首席执行官。</p>
</div><p>That wasn't the only bad news. <em>The Wall Street Journal</em> reported in May that the U.S. Department of Justice was conducting civil and criminal investigations into UnitedHealth Group's Medicare billing practices. The company confirmed in July that those investigations were indeed underway.</p>
<div class="lb-trans"><p>这并不是唯一的坏消息。《华尔街日报》在五月份报道，美国司法部正在对联合健康集团的医疗保险账单做法进行民事和刑事调查。该公司在七月份确认这些调查确实正在进行中。</p>
</div><p>But UnitedHealth Group is in good hands with former longtime CEO Stephen Hemsley back in charge. The company's current financial woes stem from higher-than-expected medical costs, particularly with its Medicare Advantage plans. Those issues can be resolved by increasing premiums, which is exactly what UnitedHealth plans to do in 2026.</p>
<div class="lb-trans"><p>但联合健康集团在前首席执行官斯蒂芬·赫姆斯利的掌舵下，依然处于良好的管理之中。该公司当前的财务困境源于高于预期的医疗成本，特别是在其医疗保险优势计划中。这些问题可以通过提高保费来解决，而这正是联合健康计划在 2026 年要做的。</p>
</div><p>Sure, the dark cloud related to the DOJ investigations will continue to hover over the company's head for a while. A previous federal probe lasted a decade. However, no evidence of wrongdoing was found in that investigation. UnitedHealth Group seems to believe there will be a similar outcome this time around, with the company stating that it &#34;has full confidence in its practices.&#34;</p>
<div class="lb-trans"><p>当然，与司法部调查相关的阴云将在一段时间内继续笼罩在公司头上。之前的一次联邦调查持续了十年。然而，在那次调查中没有发现任何不当行为的证据。联合健康集团似乎相信这次也会有类似的结果，公司表示 “对其做法充满信心”。</p>
</div><p>Billionaire investors Warren Buffett and David Tepper, along with Michael Burry of <em>The Big Short</em> fame, bought shares of the healthcare giant in the second quarter of 2025. They undoubtedly view UnitedHealth Group's valuation as attractive, with its price-to-earnings ratio at its lowest level in years.</p>
<div class="lb-trans"><p>亿万富翁投资者沃伦·巴菲特和大卫·泰珀，以及因《大空头》而闻名的迈克尔·伯里，在 2025 年第二季度购买了这家医疗巨头的股票。他们无疑认为联合健康集团的估值具有吸引力，其市盈率处于多年来的最低水平。</p>
</div><p>I suspect Buffett, Tepper, and Burry are right about UnitedHealth Group's prospects. Once the company's earnings begin to grow again next year, this beaten-down stock could rebound strongly.</p>
<div class="lb-trans"><p>我怀疑巴菲特、泰珀和伯里对联合健康集团的前景是正确的。一旦公司的收益在明年开始再次增长，这只被严重低估的股票可能会强劲反弹。</p>
</div><h2>2. Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>2. Vertex 制药</h2>
</div><p><strong>Vertex Pharmaceuticals</strong>(VRTX 0.69%) was on a roll earlier this year. However, that momentum is now long gone. The biotech stock has fallen more than 20% below its March 2025 peak.</p>
<div class="lb-trans"><p><strong>Vertex 制药</strong>（VRTX 0.69%）在今年早些时候表现出色。然而，这种势头现在已经消失。该生物技术股票的股价已下跌超过 20%，低于 2025 年 3 月的峰值。</p>
</div><p>The first warning sign for Vertex came in May with the company's weaker-than-expected first-quarter results. Revenue was lower than analysts had predicted, primarily due to the sale of copycat versions of the company's cystic fibrosis (CF) drugs in Russia, which negatively impacted sales.</p>
<div class="lb-trans"><p>Vertex 的第一个警告信号出现在五月，该公司公布的第一季度业绩低于预期。收入低于分析师的预测，主要是由于公司在俄罗斯销售的仿制版囊性纤维化（CF）药物影响了销售。</p>
</div><p>Vertex announced two pipeline setbacks earlier this month. Experimental pain drug VX-993 failed to meet the primary endpoint of a phase 2 clinical trial. The company also revealed that the U.S. Food and Drug Administration (FDA) didn't see a path forward for a broad label for Journavx in treating peripheral neuropathic pain (PNP).</p>
<div class="lb-trans"><p>Vertex 本月早些时候宣布了两个管道挫折。实验性止痛药 VX-993 未能达到二期临床试验的主要终点。该公司还透露，美国食品和药物管理局（FDA）未看到为 Journavx 在治疗外周神经病理性疼痛（PNP）提供广泛标签的前景。</p>
</div><p>While this news was disappointing, Vertex has more positives than negatives. Journavx's U.S. launch is going so well that the company is beefing up its commercialization efforts. Its newest CF therapy, Alyftrek, continues to gain steam in the market. Both Journavx and Alyftrek should become huge blockbuster drugs for Vertex in the not-too-distant future.</p>
<div class="lb-trans"><p>尽管这一消息令人失望，但 Vertex 的积极因素仍然多于消极因素。Journavx 在美国的推出进展顺利，公司正在加强其商业化努力。其最新的 CF 疗法 Alyftrek 在市场上持续获得动力。Journavx 和 Alyftrek 都应该在不久的将来成为 Vertex 的巨大畅销药。</p>
</div><p>Vertex's pipeline prospects still look promising, too. The biotech company expects to file for global regulatory approvals of type 1 diabetes therapy zimislecel and for FDA accelerated approval of povetacicept in treating IgA nephropathy next year. A late-stage clinical study is also in progress for inaxaplin targeting APOL1-mediated kidney disease. And while the FDA poured cold water on a broad PNP label for Journavx for now, Vertex is moving ahead with phase 3 studies to try to win approval in painful diabetic peripheral neuropathy.</p>
<div class="lb-trans"><p>Vertex 的管道前景仍然看好。该生物技术公司预计将在明年申请 1 型糖尿病疗法 zimislecel 的全球监管批准，并申请 FDA 加速批准 povetacicept 用于治疗 IgA 肾病。针对 APOL1 介导的肾病的晚期临床研究也在进行中。尽管 FDA 目前对 Journavx 的广泛 PNP 标签泼了冷水，但 Vertex 仍在推进三期研究，以争取在糖尿病外周神经病变中获得批准。</p>
</div><p>The consensus Wall Street 12-month price target for this biotech stock reflects an upside potential of over 21%. If Vertex's approved products and pipeline candidates fulfill their promise, its stock should be able to skyrocket much more than that over the next few years.</p>
<div class="lb-trans"><p>华尔街对这只生物技术股票的 12 个月共识目标价反映出超过 21% 的上涨潜力。如果 Vertex 的已批准产品和管道候选药物兑现其承诺，其股票在未来几年内应该能够大幅飙升。</p>
</div>

两只被严重低估的股票具有巨大的上涨潜力